Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedPlain Language Summary added and page updated to Revision 3.4.2 with new dates; funding-status notice removed.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a government funding lapse notice and updated the site to revision v3.4.1. These changes are administrative and do not modify the trial details, eligibility criteria, endpoints, or study data.SummaryDifference0.2%

- Check28 days agoChange DetectedShow glossary is now displayed; Last Update Submitted that Met QC Criteria and Last Update Posted timestamps are displayed; No FEAR Act Data is shown and Revision indicator updated to v3.4.0. The previous items Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page now shows Revision: v3.3.4 added and Revision: v3.3.3 removed.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Locations section now lists a large number of trial sites across the United States, Canada, Australia, and many other countries, detailing states, provinces, and cities. This expands the geographic coverage of the LEAP-002 study.SummaryDifference2%

- Check91 days agoChange DetectedPublications description text was slightly revised from 'results of the study' to 'study results', and the page now lists Revision: v3.3.2 (replacing the previous v3.2.0).SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.